The Costs of Treating Febrile Neutropenia in Patients with Malignant Blood Disorders

Publisher Website
Google Scholar
Abstract
Retrospective dala were collected over a 1-year period from the medical records of palicms admitted 10 a district general hospital, either with febrile ncutropenia or who developed this complication whilst receiving inpatient chemotherapy. Costs were calculated for inpatient stay, drug treatment and diagnostic tests. The median total cost for 46 episodes of febrile neutropenia were £2068.35 and the median total costs, per day was £139.41. Inpatient bed-days accounted for 57.8% of total costs, followed by drug treatment at 25.8% and diagnostic tests at 16.4%. The costs of blood products were excluded since they are frequently administered irrespective of the neutropenia. This study serves as a useful pointer to the expenditure in measurable antibiotic costs and investigations in patients with malignant blood disorders who develop febrile neutropenia.